Ph2 PoC in IPF
Research payments
$353,244
Through program year 2025, $353,244 in research payments was reported against Ph2 PoC in IPF, across 51 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $24,604 | 15 |
| 2024 | Research | $328,640 | 36 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shilpa Johri Richmond, VA Named on 10 payments
- Dominic Titone Lakewood, CO Named on 9 payments
- Thomas Kaelin N Charleston, SC Named on 3 payments
- Oscar Parodi Ortiz De Villate Warren, MI Named on 3 payments
- Aaron Milstone Franklin, TN Named on 3 payments
- David Maybee New Bern, NC Named on 3 payments
- Ryan Brimeyer West Des Moines, IA Named on 2 payments
- Gerard Criner Philadelphia, PA Named on 2 payments
- Neil Ettinger Chesterfield, MO Named on 2 payments
- Sandeep Bansal Du Bois, PA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.